Island Pharmaceuticals (ASX:ILA)
ASX announcement history & article coverage
Transparent by design.
Announcments by Island Pharmaceuticals (ASX:ILA) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification regarding unquoted securities - ILA
Notification regarding unquoted securities - ILA
Notification regarding unquoted securities - ILA
Notification regarding unquoted securities - ILA
Texas Biomed SOW accelerates pivotal FDA pathway
Island Pharmaceuticals advances Galidesivir dose optimisation with Texas Biomed for pivotal FDA Animal Rule study
Investor Presentation - Ebola Clinical Program
Island Pharmaceuticals advances Galidesivir antiviral with government approvals and clinical data plans amid urgent Ebola outbreak
Notification of cessation of securities - ILA
Galidesivir approved for treatment use in in Ebola epidemic
Trading Halt
Pause in Trading
Island Pharmaceuticals Limited trading paused pending further announcement
Singapore Patent Expands Island's ISLA 101 Viral Protection
Island Pharmaceuticals secures Singapore patent for ISLA-101 antiviral treatment
FDA Grants Orphan Designation for Galidesivir in Marburg
Galidesivir granted FDA Orphan Drug Designation for Marburg virus disease
Investor Presentation - Asia Dengue Summit
Island Pharmaceuticals presents positive Phase 2a dengue trial results at Asia Dengue Summit
Investor presentation (updated)
Investor presentation
Island Pharmaceuticals advances Galidesivir antiviral with FDA Animal Rule pathway and biodefense focus
Island Secures USAMRIID Support for Galidesivir Study
Island Pharmaceuticals expands CRADA with USAMRIID for Galidesivir Marburg dose optimisation study
Island Advances Galidesivir GMP Manufacturing for Biodefence
Island Pharmaceuticals begins GMP manufacturing of Galidesivir to support pivotal Marburg study and biodefence opportunities
Island Adds Biodefence Leader as Filovirus Risks Escalate
Island Pharmaceuticals appoints Raymond Taylor to accelerate Galidesivir antiviral development and US Government engagement
Island Bolsters US Biodefence Readiness Ahead of Trials
Island Pharmaceuticals boosts US biodefense ties with senior appointment and MC2 roles ahead of Galidesivir FDA Animal Rule studies
Cleansing Notice
Application for quotation of securities - ILA
Quarterly Appendix 4C and Activities Report
Island Pharmaceuticals Advances Galidesivir with FDA Alignment, Strategic Partnerships, and $9M Funding
